Novartis Gene Therapies clinical trials
Acquired by Novartis, May 15, 2018 · source ↗
The registry lists 8 studies whose lead sponsor is Novartis Gene Therapies. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 24, 2026.
- 8studies on the registry
- 0open to participants now
- 1phase 3 study under way
Before and after it joined Novartis
- First submitted before Novartis Gene Therapies became part of Novartis
- 6
- First submitted after Novartis Gene Therapies became part of Novartis
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Novartis Gene Therapies’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- onasemnogene abeparvovec5 in phase 30 open · 7
All 8 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 16
- 317
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Novartis Gene Therapies8 studies
Something wrong with this grouping? Tell us on the Novartis page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Novartis studies →
- Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioiActive, not recruitingNCT04042025Phase 3
Sponsor listed in the registry: Novartis Gene Therapies · First submitted after Novartis Gene Therapies became part of Novartis
- Long-Term Follow-up Study for Patients From AVXS-101-CL-101Active, not recruitingNCT03421977
Sponsor listed in the registry: Novartis Gene Therapies · First submitted before Novartis Gene Therapies became part of Novartis
- Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1CompletedNCT03461289Phase 3
Sponsor listed in the registry: Novartis Gene Therapies · First submitted before Novartis Gene Therapies became part of Novartis
- Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular AtrophyTerminatedNCT03381729Phase 1
Sponsor listed in the registry: Novartis Gene Therapies · First submitted before Novartis Gene Therapies became part of Novartis
- Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2CompletedNCT03505099Phase 3
Sponsor listed in the registry: Novartis Gene Therapies · First submitted before Novartis Gene Therapies became part of Novartis
- Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1CompletedNCT03306277Phase 3
Sponsor listed in the registry: Novartis Gene Therapies · First submitted before Novartis Gene Therapies became part of Novartis
- Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 CopiesCompletedNCT03837184Phase 3
Sponsor listed in the registry: Novartis Gene Therapies · First submitted after Novartis Gene Therapies became part of Novartis
- Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1CompletedNCT02122952Phase 1
Sponsor listed in the registry: Novartis Gene Therapies · First submitted before Novartis Gene Therapies became part of Novartis